Format

Send to

Choose Destination
Oncotarget. 2010 Jul;1(3):228-32.

Targeting Rb mutant cancers by inactivating TSC2.

Author information

1
Ben May Department for Cancer Research, Chicago, IL 60637, USA.

Abstract

Retinoblastoma (Rb), a tumor suppressor gene, is inactivated in many types of cancer. However little is known about how the loss of Rb function can be targeted in cancer therapies. We have identified that inactivation of TSC2 in Rb mutant cancer cells will induce a synergistic cell death. The synergistic cell death is due to an increase in cellular stress including metabolic, ER, and oxidative stress. Therefore, inactivation of TSC2 and chemothereputics that result in induction of cellular stress may be a novel and effective way to treat cancers containing inactivated Rb.

KEYWORDS:

ROS; Rb; SOD2; TOR; TSC2; synthetic lethal

PMID:
20706560
PMCID:
PMC2920149
DOI:
10.18632/oncotarget.130
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center